CRISPR Therapeutics AGCRSPNASDAQ
LOADING
|||
CRSP Revenue Growth (YoY Quarterly)•+0.00%
SAPRO
Growth Metrics
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | -82.50% | +71.63% | -100.00% | +0.00% |
| Gross Profit Growth | +0.00% | -80.56% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | -180.21% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | -192.82% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | -141.76% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | -139.29% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | -140.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +7.33% | +7.25% | +5.07% | +2.53% | +7.12% |
| Weighted Average Shares Diluted Growth | +7.33% | +5.09% | +5.07% | +2.53% | +7.12% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | -149.15% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | -149.67% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | -87.50% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +8.11% | +0.56% | -11.19% | -13.25% | -0.48% |
| Book Value per Share Growth | +4.60% | -4.32% | -16.46% | -15.75% | -7.79% |
| Debt Growth | -5.81% | -6.26% | -6.63% | -6.85% | -7.26% |
| R&D Expense Growth | -9.41% | -13.65% | +1.61% | +120.59% | -28.31% |
| SG&A Expenses Growth | -4.77% | +9.98% | +7.48% | -2.90% | -2.80% |
1 / 4